Thursday, November 19, 2026
RSS

Pharmaceutical

Alnylam’s $25 Million Regeneron Milestone Puts Its RNAi Model in Focus

Alnylam’s $25 million Livsayis milestone highlights the commercial value of its RNAi platform and partnership-driven revenue model.

November 19, 2026
Pharmaceutical

Black Diamond Gains as FDA Maps Accelerated-Approval Path for Silevertinib

FDA guidance on accelerated approval and a broad EGFR mutation definition may reduce uncertainty around Black Diamond’s silevertinib program.

Nov 19
Pharmaceutical

J&J Seeks FDA Approval to Expand CAPLYTA Into Bipolar Mania

J&J’s CAPLYTA filing could create a fifth potential indication, broadening its psychiatric franchise even as JNJ shares were reported lower.

Nov 19
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Pharmaceutical

ADC Therapeutics Pitches Zynlonta Expansion as a Commercial Growth Driver

ADC Therapeutics is emphasizing Zynlonta’s market opportunity and broader commercial availability as it seeks a more dur…

Nov 19, 2026
Pharmaceutical

Merck Maps Out Its Post-Keytruda Growth Strategy With Nine New Medicines

Merck is positioning nine newer medicines and vaccines, including intismeran, as part of its strategy for the post-KEYTR…

Nov 19, 2026
Pharmaceutical

Regeneron Buy Rating Reaffirmed After Fresh FDA Approval

Truist reiterated its Buy rating on $REGN after a new FDA approval, giving traders a concrete catalyst for reassessing i…

Nov 19, 2026
Pharmaceutical

Q32 Bio Slides as Conference Commentary Raises Phase 3 Volatility

Q32 Bio shares fell 2.9% premarket after Phase 3 commentary at the Jefferies conference, underscoring the risks of small…

Nov 18, 2026
Pharmaceutical

Biogen’s Mixed Alzheimer’s Data Leaves Investors Weighing CELIA’s Signal

Biogen’s two-year CELIA data showed broad clinical improvement at 60 mg, but the MMSE exception leaves investors weighin…

Nov 18, 2026
Pharmaceutical

Bristol Myers Squibb’s KarXT Data Puts Schizophrenia Growth Story in Focus

Preliminary KarXT data puts Bristol Myers Squibb’s psychiatry pipeline under the microscope, with investors watching for…

Nov 18, 2026
Pharmaceutical

GSK Wins FDA Approval for Nelkarmi After $10.6 Billion Nuvalent Acquisition

Nelkarmi’s FDA approval gives GSK an early validation point for its $10.6 billion Nuvalent acquisition and strengthens i…

Nov 18, 2026
Pharmaceutical

Rythm Pharmaceuticals Jumps on Reported $150 Offer From Eli Lilly With CVR

Rythm Pharmaceuticals gained after a report of a $150-per-share Eli Lilly offer with a CVR, creating premium potential b…

Nov 18, 2026
Pharmaceutical

Cardiff Oncology’s Phase III Push Puts Trial Durability in the Spotlight

Cardiff Oncology’s UBS conference update puts its Phase III timeline—and the durability question—at the center of the CR…

Nov 17, 2026